Physiologic Pacing for First-Degree Heart Block
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if physiologic pacing will improve symptoms and outcomes in patients with symptomatic first-degree heart block (pr interval ≥250ms).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Physiologic Pacing for First-Degree Heart Block?
Research shows that pacing the left bundle branch can improve heart function in patients with heart failure and left bundle branch block, leading to better clinical outcomes. Additionally, His bundle pacing has been effective in improving heart function in patients with atrioventricular block and left bundle branch block, suggesting potential benefits for similar heart conditions.12345
Is physiologic pacing safe for humans?
How is physiologic pacing different from other treatments for first-degree heart block?
Physiologic pacing, including His bundle pacing and left bundle branch pacing, is unique because it mimics the heart's natural electrical pathways, potentially leading to more natural heart function compared to traditional pacemakers that do not engage the heart's conduction system as directly.611121314
Eligibility Criteria
This trial is for individuals with symptomatic first-degree heart block, which means their hearts have a specific type of electrical delay. Participants must meet certain health criteria to join, but the provided information does not specify these details.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Evaluation
Patients are evaluated for baseline symptoms, exercise capacity, arrhythmia burden, and patient activity
Treatment
Patients undergo left bundle pacing and are randomized to DDD-50 vs MVP-50 with a crossover at 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including quality of life, exercise capacity, patient activity, and atrial fibrillation burden
Treatment Details
Interventions
- Physiologic Pacing
Physiologic Pacing is already approved in European Union, United States for the following indications:
- Heart failure
- Symptomatic first-degree heart block
- High-grade AV block
- Complete heart block
- Heart failure
- Symptomatic first-degree heart block
- High-grade AV block
- Complete heart block
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ascension Health
Lead Sponsor
Medtronic
Industry Sponsor
Geoff Martha
Medtronic
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Richard Kuntz
Medtronic
Chief Medical Officer since 2023
MD, MSc